1 / 60

Opioid Tapering for Chronic Opioid Users: Parts I and II

Opioid Tapering for Chronic Opioid Users: Parts I and II. Corey J. Hayes, PharmD, PhD, MPH Assistant Professor Departments of Psychiatry and Biomedical Informatics University of Arkansas for Medical Sciences College of Medicine Research Health Scientist

gino
Download Presentation

Opioid Tapering for Chronic Opioid Users: Parts I and II

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Opioid Tapering for Chronic Opioid Users: Parts I and II Corey J. Hayes, PharmD, PhD, MPH Assistant Professor Departments of Psychiatry and Biomedical Informatics University of Arkansas for Medical Sciences College of Medicine Research Health Scientist VA HSR&D Center for Mental Health and Outcomes Research Central Arkansas Veterans Healthcare System Primary Email: cjhayes@uams.edu

  2. Part I: CDC Guidelines for Prescribing Opioids for Chronic Pain and Tapering Logistics

  3. CDC Guidelines: What They Are and Are Not • Are Recommendation for: • Primary Care Providers • Family medicine, Internal medicine • Treating patients >18 years with chronic pain • Pain longer than 3 months or past time of normal tissue healing • Outpatient settings • Are Not: • Guidelines on Treatment of Cancer-Related Pain • End of Life Care • Palliative Care

  4. 12 Recommendations for 3 Areas • Determining When to Initiate or Continue Opioids for Chronic Pain • 3 Recommendations • Opioid Selection, Dosage, Duration, Follow-Up, and Discontinuation • 4 Recommendations • Assessing Risk and Addressing Harms of Opioid Use • 5 Recommendations

  5. Recommendation 1 • Non-pharmacologic therapy and non-opioid pharmacologic therapy are preferred • Non-Pharm Therapy: exercise or cognitive behavioral therapy (CBT), weight loss, interventional procedures • Non-Opioid Pharm therapy (NSAIDs, acetaminophen, anticonvulsants, certain antidepressants) • Consider opioid therapy only if expected benefits for both pain and function > risks • If opioids are used, combine with non-pharmacologic therapy and non-opioid pharmacologic therapy • (Recommendation category: A, evidence type: 3)-may change with new studies

  6. Recommendation 2 • Before starting, establish realistic treatment goals for pain and function: • Determine how effectiveness will be measured • Establish treatment goals for pain relief AND function • Continue opioid therapy only if there is clinically meaningful improvement in pain and function > risks: • Use PEG (Pain, Enjoyment of Life, General Activity, each 0-10) Assessment Scale, 30% change is clinically meaningful • (Recommendation category: A, evidence type: 4)

  7. PEG Scale Krebs et al. “Development and Initial Validation of the PEG, a Three-item Scale Assessing Pain Intensity and Interference.” J Gen Intern Med. 2009 Jun; 24(6): 733–738.

  8. Recommendation 3 • Before starting and periodically: • discuss risks and realistic benefits of opioids • patient and clinician responsibilities for managing therapy • This could look like discussions of: • serious and common adverse effects • increased risks of overdose with high doses and taking with other drugs and alcohol • reassessment of effectiveness • use of PDMP and UDS • risks to family members and individuals in the community • (Recommendation category: A, evidence type: 3)

  9. Area 2 Opioid Selection, Dosage, Duration, Follow-Up, and Discontinuation

  10. Recommendation 4 • When starting opioid therapy for chronic pain prescribe IR opioids and not ER/LA opioids: • Higher risk than initiating on IR opioids • No evidence that ER/LA is more effective or safer • Avoid IR and ER/LA combos-higher risk with no benefit • Methadone and Fentanyl only used by experience prescribers • (Recommendation category: A, evidence type: 4)

  11. Recommendation 5 • Prescribe the lowest effective dosage • Carefully reassess individual benefits/risks when≥50 MME/day and: • Increase frequency of follow-up • Consider offering naloxone • Avoid increasing dosage to ≥90 MME/dayor carefully justify • (Recommendation category: A, evidence type: 3)

  12. Recommendation 6 • With acute pain, prescribe the lowest effective dose of IR opioids, no ER/LA opioids • Prescribe no greater quantity than needed, no “just in case” • 3 days or less will often be sufficient; more than 7 days will rarely be needed • This does not address post-surgical pain • “Opioid treatment for post-surgical pain is outside the scope of this guideline but has been addressed elsewhere” • (Recommendation category: A, evidence type: 4)

  13. Recommendation 7 • Evaluate benefits/harms: • within 1-4 weeks of starting or increasing the dose • at least every 3 months thereafter • If benefits < harms, optimize other therapies andtaper opioids • (Recommendation category: A, evidence type: 4)

  14. Recommendation 7 Continued • At follow up, ask 4 things: • 1. Do opioids continue to meet treatment goals? • 2. Are there common or serious adverse events or early warning signs? • 3. Do benefits > risks? • 4. Can opioid dosage can be reduced or opioids can be discontinued? • Instancing when to really consider tapering (10% per week): • 1. no sustained clinically meaningful improvement in pain and function • 2. opioid dosages >50 MME/day without evidence of benefit • 3. concurrent benzodiazepines that can’t be tapered off • 4. patients experience overdose, other serious adverse events, warning signs

  15. Area 3 Assessing Risk and Addressing Harms of Opioid Use

  16. Recommendation 8 • Incorporate strategies to mitigate risk • Risk mitigation tips: • Avoid opioids with patients with sleep disorders • Use caution in renal or hepatic insufficiency or >65 years of age • Adequately treat MH disorders • Screen for SUDs and Developing Risk (Opioid Risk Tool, Brief Risk Interview, etc) • Consider offering naloxone when certain factors arise: • history of overdose or SUD • higher opioid dosages (≥50 MME/day) • concurrent benzodiazepine use • (Recommendation category: A, evidence type: 4)

  17. Recommendation 9 • Review the PDMP data • What to look for in PDMP data review: • receiving other opioids • dangerous combinations • How often to review PDMP data: • when starting opioids • with every prescription or up to every 3 months • If misusing, do not dismiss patient-offer lifesaving info and interventions • (Recommendation category: A, evidence type: 4)

  18. Recommendation 10 • When prescribing for chronic pain, use UDS before starting opioids and at least annually • Before ordering UDS: • explain to patients that testing is intended to improve their safety • explain expected results • ask patients whether there might be unexpected results • Verify unexpected, unexplained results using specific test • Immunoassay is typically followed by GC/MS if positive • Do not dismiss patients from care based on a UDS result • (Recommendation category: B, evidence type: 4)

  19. Recommendation 11 • Avoid prescribing opioids and benzodiazepines concurrently whenever possible • Taper Benzos gradually • Offer evidence-based psychotherapies for anxiety: • 1. CBT • 2. specific anti-depressants approved for anxiety • 3. other non-benzodiazepine medications approved for anxiety—Buspar takes time • (Recommendation category: A, evidence type: 3)

  20. Recommendation 12 • Offer or arrange evidence-based treatment for patients with opioid use disorder • Assess for OUD using DSM-5 criteria. 11 criteria and need 2 of the 11--not both tolerance and withdrawal • If present, offer or arrange MAT and behavioral therapies: • Buprenorphine • Methadone maintenance therapy • Oral or long-acting injectable formulations of naltrexone (for highly motivated non-pregnant adults) • (Recommendation category: A, evidence type: 2)

  21. CDC Guideline Mobile App

  22. Tapering Logistics

  23. Three Main Resources: CDC, Mayo Clinic, and VA • https://www.cdc.gov/drugoverdose/pdf/clinical_pocket_guide_tapering-a.pdf • https://www.mayoclinicproceedings.org/article/S0025-6196(15)00303-1/fulltext • https://www.pbm.va.gov/AcademicDetailingService/Documents/Pain_Opioid_Taper_Tool_IB_10_939_P96820.pdf

  24. When should I consider tapering for my patient according to CDC? • Patient does not have a clinically meaningful improvement in pain and function (e.g., at least 30% improvement on the 3-item PEG scale) • is on dosages ≥ 50 MME/day without benefit or opioids are combined with benzodiazepines • shows signs of substance use disorder (e.g. work or family problems related to opioid use, difficulty controlling use) • experiences overdose or other serious adverse event • shows early warning signs for overdose risk such as confusion, sedation, or slurred speech https://www.cdc.gov/drugoverdose/pdf/clinical_pocket_guide_tapering-a.pdf

  25. When should I consider tapering for my patient according to VA? https://www.pbm.va.gov/AcademicDetailingService/Documents/Pain_Opioid_Taper_Tool_IB_10_939_P96820.pdf

  26. When should I consider tapering for my patient according to Mayo Clinic?

  27. Screen/maximize treatment before tapering: • Mental Health Disorders • One study showed post-tapering depression scores to be the sole predictor of relapse • OUD and other SUDs • “Moral Injury” (Inner Conflict) • Central Sensitization (e.g. fibromyalgia, chronic headaches) • Medical complications (e.g., lung disease, hepatic disease, renal disease, or fall risk) • Sleep disorders including sleep apnea https://www.pbm.va.gov/AcademicDetailingService/Documents/Pain_Opioid_Taper_Tool_IB_10_939_P96820.pdf http://www.med.umich.edu/1info/FHP/practiceguides/pain/Opioid.Taper.Mayo.pdf

  28. How to Taper • Go Slow-10% per week or slower • Consult-specialists needed • Support-naloxone, MH provider • Encourage-inform patient that most, over time, have improved function https://www.cdc.gov/drugoverdose/pdf/clinical_pocket_guide_tapering-a.pdf

  29. Use the Following Strategies in Tapering: • Discussion • Ask about Goals • Education https://www.pbm.va.gov/AcademicDetailingService/Documents/Pain_Opioid_Taper_Tool_IB_10_939_P96820.pdf

  30. Discussion • Listen to the patient’s story • Let the patient know that you believe that their pain is real • Include family members or other supporters in the discussion • Acknowledge the patient’s fears about tapering [use Motivational Interviewing (MI) techniques] https://www.pbm.va.gov/AcademicDetailingService/Documents/Pain_Opioid_Taper_Tool_IB_10_939_P96820.pdf

  31. Ask about Goals • Draw out their goals for life (not just being pain-free) • Have the patient fill out the Personal Health Inventory (PHI) • https://www.va.gov/PATIENTCENTEREDCARE/docs/Personal-Health-Inventory-final-508-WHFL.pdf • Ask how we can support them during the taper https://www.pbm.va.gov/AcademicDetailingService/Documents/Pain_Opioid_Taper_Tool_IB_10_939_P96820.pdf

  32. Educate the Patient • Offer physical therapy and Complementary and Integrative Health (CIH) • acupuncture, meditation, yoga • Offer non-opioid pain medications • Provide opioid overdose education and prescribe naloxone to patients at increased risk of overdose • can lose tolerance in a week • at risk of an overdose if they resume their original dose https://www.pbm.va.gov/AcademicDetailingService/Documents/Pain_Opioid_Taper_Tool_IB_10_939_P96820.pdf

  33. https://www.pbm.va.gov/AcademicDetailingService/Documents/Pain_Opioid_Taper_Tool_IB_10_939_P96820.pdfhttps://www.pbm.va.gov/AcademicDetailingService/Documents/Pain_Opioid_Taper_Tool_IB_10_939_P96820.pdf

  34. Patient Follow Up https://www.pbm.va.gov/AcademicDetailingService/Documents/Pain_Opioid_Taper_Tool_IB_10_939_P96820.pdf

  35. General Approach • Determine patient’s total amount of opioid patient is currently taking every 24 hours • Use conversion chart/app to convert from opioid dose patient is currently taking to morphine equivalent • If converting from parenteral dosage form, convert to parenteral morphine first then from parenteral to oral morphine • Use conversion chart/app to convert from oral morphine equivalent to dose of desired opioid • Decrease total daily dose by up to 50% - 75% to account for incomplete cross tolerance between opioids

  36. Equianalgesic Chart* (example) *Compiled from Johns Hopkins opioid program (hopontheweb.org) and CMS (https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Opioid-Morphine-EQ-Conversion-Factors-March-2015.pdf)

  37. Opioid Tapering Tools • Guides or Toolkits: • https://www.pbm.va.gov/AcademicDetailingService/Documents/Pain_Opioid_Taper_Tool_IB_10_939_P96820.pdf • https://www.cdc.gov/drugoverdose/pdf/clinical_pocket_guide_tapering-a.pdf • http://www.partnershiphp.org/Providers/HealthServices/Documents/Managing%20Pain%20Safely/TAPERING%20TOOLKIT_FINAL.pdf • Templates or Opioid Tapering Agreements: • https://thewellhealth.ca/wp-content/uploads/2018/03/20180305-Opioid-Tapering-Tool-Fillable.pdf • http://www.med.umich.edu/1info/FHP/practiceguides/pain/Opioid.Taper.Mayo.pdf • http://www.rxfiles.ca/rxfiles/uploads/documents/opioid-taper-template.pdf • Calculators: • https://www.hca.wa.gov/search/site/tapering%20calculator?section=%2A • “Slow and Steady Wins the Race” • https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2672574?resultClick=1

  38. “Slow and Steady Wins the Race” • “Patient-Centered Prescription Opioid Tapering in Community Outpatients With Chronic Pain” May 2018 JAMA Intern Med. • Pain Clinic • Of 110 eligible patients, 82 agreed to taper after education (75%) • Tapering over 4 months, not necessarily discontinuing • Opioid dosages were reduced up to 5% through up to 2 dose reductions in month 1 • to minimize negative physical and emotional response, withdrawal symptoms, and to facilitate patient confidence in the process. • In months 2 to 4, patients were asked to further reduce use by as much as 10% per week but were tailored https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2672574?resultClick=1

  39. “Slow and Steady Wins the Race” • Demographics: 51 y/o, 60% female • 31 of 82 did not complete a 4 month f/u survey • Marijuana use positively correlated with study completion • Median MEDD for the patients went from 288 to 150 • Neither pain intensity nor pain interference increased https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2672574?resultClick=1

  40. “Slow and Steady Wins the Race” https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2672574?resultClick=1

  41. Questions?

  42. Part II: Withdrawal and Patient Cases

  43. Progression of Withdrawal Symptoms https://www.pbm.va.gov/AcademicDetailingService/Documents/Pain_Opioid_Taper_Tool_IB_10_939_P96820.pdf

  44. https://www.mayoclinicproceedings.org/article/S0025-6196(15)00303-1/pdfhttps://www.mayoclinicproceedings.org/article/S0025-6196(15)00303-1/pdf

  45. 5-12=Mild; 13-24=Moderate; 25-36=Moderately Severe; >36=Severe Withdrawal https://www.drugabuse.gov/sites/default/files/files/ClinicalOpiateWithdrawalScale.pdf http://www.med.umich.edu/1info/FHP/practiceguides/pain/Opioid.Taper.Mayo.pdf

  46. Withdrawal Symptom Treatment https://www.pbm.va.gov/AcademicDetailingService/Documents/Pain_Opioid_Taper_Tool_IB_10_939_P96820.pdf

  47. Withdrawal Symptom Treatment https://www.pbm.va.gov/AcademicDetailingService/Documents/Pain_Opioid_Taper_Tool_IB_10_939_P96820.pdf

  48. https://www.aafp.org/dam/AAFP/documents/patient_care/pain_management/tapering-resource.pdfhttps://www.aafp.org/dam/AAFP/documents/patient_care/pain_management/tapering-resource.pdf

  49. http://www.med.umich.edu/1info/FHP/practiceguides/pain/Opioid.Taper.Mayo.pdfhttp://www.med.umich.edu/1info/FHP/practiceguides/pain/Opioid.Taper.Mayo.pdf

  50. Post-Acute Withdrawal Syndrome (PAWS) • Not an official diagnosis • Cluster of ongoing withdrawal symptoms, mostly psychological and mood-related, that can continue after acute withdrawal symptoms have gone away • Typical symptoms: • Cravings • Exhaustion • Cognitive Impairment • Stress Sensitivity https://www.hazeldenbettyford.org/articles/carty/post-acute-withdrawal-syndrome https://americanaddictioncenters.org/withdrawal-timelines-treatments/post-acute-withdrawal-syndrome/

More Related